共 40 条
- [31] Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 5441 - 5450
- [32] Fixed or Adjustable Maintenance-Dose Budesonide/Formoterol Compared with Fixed Maintenance-Dose Salmeterol/Fluticasone Propionate in Asthma Patients Aged ≥16 YearsPost Hoc Analysis of a Randomized, Double-Blind/Open-Label Extension, Parallel-Group Study Clinical Drug Investigation, 2010, 30 : 439 - 451
- [34] Fixed or Adjustable Maintenance-Dose Budesonide/Formoterol Compared with Fixed Maintenance-Dose Salmeterol/Fluticasone Propionate in Asthma Patients Aged ≥16 Years Post Hoc Analysis of a Randomized, Double-Blind/Open-Label Extension, Parallel-Group Study CLINICAL DRUG INVESTIGATION, 2010, 30 (07) : 439 - 451
- [37] Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study (vol 14, pg 5441, 2020) DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 515 - 516
- [40] Relative Effectiveness of Budesonide/Formoterol and Fluticasone Propionate/Salmeterol in a 1-Year, Population-Based, Matched Cohort Study of Patients With Chronic Obstructive Pulmonary Disease (COPD): Effect on COPD-Related Exacerbations, Emergency Department Visits and Hospitalizations, Medication Utilization, and Treatment Adherence CLINICAL THERAPEUTICS, 2010, 32 (07) : 1320 - 1328